" class="no-js "lang="en-US"> Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries - Medtech Alert
Thursday, March 28, 2024

Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement that enables the European Union (EU) and European Economic Area (EEA) countries to donate doses of the Moderna COVID-19 vaccine that they have purchased under the EU Vaccines Strategy to COVAX on an ongoing basis for delivery in 2021. This initiative, led by France, Sweden, and Norway is expected to enable the donation of more than 70 million doses of Moderna vaccine in 2021, including an initial donation of 15 million doses by France and 40 million doses by Germany.

This agreement provides that donations of Moderna vaccine by EU and EEA countries to COVAX will be directed to the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. COVAX is a global initiative co-led by Gavi, the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.

“I would like to thank the governments of France, Sweden and Norway, the EU and EEA countries and Gavi for this agreement to facilitate the donation of doses of the Moderna COVID-19 vaccine from the EU Member States to COVAX to help end the pandemic in low-income countries,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We believe that dose sharing, among other strategies, will help ensure an equitable global distribution of COVID-19 vaccines. We remain focused on implementing a comprehensive and always evolving strategy to ensure that low-income countries get access to our vaccine as we seek to help end the pandemic around the world.”

Dose sharing is an important pillar of Moderna’s comprehensive plan to bring vaccines to as many people as possible around the world. On October 21, Stéphane Bancel published a letter on the path forward for global vaccination. On October 8, Stéphane Bancel published a letter on Moderna’s commitment to global vaccine access.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more